Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605
Author:
Funder
National Institutes of Health
National Cancer Institute
Genentech
NCI
Publisher
Elsevier BV
Subject
Urology
Reference23 articles.
1. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline;Chang;J Urol,2017
2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000
3. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle–invasive bladder cancer treated with bacillus Calmette-Guerin;Lobo;Eur Urol Oncol,2022
4. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients;Martin-Doyle;J Clin Oncol,2015
5. The treated natural history of high risk superficial bladder cancer: 15-year outcome;Cookson;J Urol,1997
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024;Pharmaceutics;2024-08-30
2. Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer;annals of urologic oncology;2024-08-29
3. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer;BJU International;2024-08-25
4. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23
5. Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification;Nature Reviews Urology;2024-08-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3